Pyrrolidine derivatives as nk-3 receptor antagonists

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein
• Ar1 is aryl or heteroaryl;
• Ar2 is aryl or heteroaryl;
• R1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, —S(O)2-lower alkyl, —S(O)2-di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C(O)-lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or heteroaryl optionally substituted by lower alkyl;
• R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano;
• R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen;
• n is 1, 2 or 3;
• wherein when n is 2 or 3, each R1 is the same or different;
• o is 1, 2 or 3;
• wherein when o is 2 or 3, each R2 is the same or different;
• and
• p is 1, 2 or 3;
• wherein when p is 2 or 3, each R4 is the same or different;
• or a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof and a pharmaceutically acceptable carrier.